Clinical Trial Update: A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating SHR3162 with Apatinib or SHR3162 alone in metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Apatinib Mesylate Tablets (Apatinib)
• SHR3162 (SHR3162)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 2 | Status: COMPLETED